Cohort 2, added following a regulatory request, enrolled 517 patients with 1-3 positive ALNs with lower grade and tumor size (grade <3 and tumor size <5 cm) but biologically high risk based on proliferation rate (Ki-67 ≥ 20%). Here, MKI67 is linked to neoplasm.